Q2 EPS Estimates for Globus Medical Boosted by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Equities research analysts at Roth Capital lifted their Q2 2025 earnings per share (EPS) estimates for shares of Globus Medical in a research note issued to investors on Monday, July 21st. Roth Capital analyst J. Wittes now expects that the medical device company will earn $0.76 per share for the quarter, up from their previous forecast of $0.75. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical’s Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $3.15 EPS, Q2 2026 earnings at $0.91 EPS, FY2026 earnings at $3.70 EPS and FY2027 earnings at $3.97 EPS.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 8th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by ($0.06). The firm had revenue of $598.12 million for the quarter, compared to analysts’ expectations of $629.74 million. Globus Medical had a return on equity of 10.52% and a net margin of 7.39%. The firm’s revenue was down 1.4% on a year-over-year basis. During the same period last year, the company earned $0.72 earnings per share.

Several other research firms have also weighed in on GMED. Needham & Company LLC restated a “hold” rating on shares of Globus Medical in a report on Monday. BTIG Research restated a “neutral” rating on shares of Globus Medical in a report on Tuesday, May 27th. Barclays restated an “overweight” rating on shares of Globus Medical in a report on Tuesday, June 10th. JMP Securities restated a “market perform” rating on shares of Globus Medical in a report on Tuesday, May 27th. Finally, Truist Financial decreased their price target on Globus Medical from $80.00 to $68.00 and set a “hold” rating on the stock in a report on Monday, May 12th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $90.09.

Globus Medical Price Performance

Shares of GMED opened at $53.26 on Thursday. The stock has a market capitalization of $7.21 billion, a price-to-earnings ratio of 39.75, a price-to-earnings-growth ratio of 1.58 and a beta of 1.19. Globus Medical has a 1 year low of $51.87 and a 1 year high of $94.93. The business’s 50 day simple moving average is $58.33 and its 200-day simple moving average is $71.21.

Institutional Trading of Globus Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Berry Wealth Group LP grew its position in shares of Globus Medical by 4.2% during the 1st quarter. Berry Wealth Group LP now owns 3,553 shares of the medical device company’s stock worth $260,000 after buying an additional 144 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Globus Medical by 2.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,787 shares of the medical device company’s stock worth $479,000 after buying an additional 150 shares in the last quarter. HB Wealth Management LLC grew its position in shares of Globus Medical by 4.7% during the 1st quarter. HB Wealth Management LLC now owns 3,804 shares of the medical device company’s stock worth $278,000 after buying an additional 170 shares in the last quarter. Whittier Trust Co. grew its position in shares of Globus Medical by 46.5% during the 1st quarter. Whittier Trust Co. now owns 580 shares of the medical device company’s stock worth $42,000 after buying an additional 184 shares in the last quarter. Finally, Parallel Advisors LLC grew its position in shares of Globus Medical by 62.1% during the 1st quarter. Parallel Advisors LLC now owns 504 shares of the medical device company’s stock worth $37,000 after buying an additional 193 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical declared that its board has initiated a share repurchase program on Thursday, May 15th that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the medical device company to reacquire up to 6.3% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its shares are undervalued.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.